This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Other KOLs have communicated that Dupixent is to dominate the biologics market after receiving both EMA and FDA approval, filling a gap in the COPD market. The changes made by GOLD have communicated that ICS/LABA fixed-dose combinations should not be used, which has been reflected in the COPD report, highlighting a 1.4 billion by 2033.”
from 2022 to 2027. Specifically, she engaged with several important stakeholders and received valuable information about future sales and marketing strategies, decision-making vision, and innovation trends among Chinese pharmaceuticalcompanies. This role is significant because the pharma market in APAC is increasing.
As a result, some pharmaceuticalcompanies are turning to third parties. GlobalData forecasts Biologics to significantly overtake sales of small molecules by $120 billion by 2027. Moreover, skilled manpower is required to run these facilities. Please check your email to download the Whitepaper.
A Pliant spokesperson said, “This successful transaction, along with existing cash, cash equivalents, loan agreement and short-term investments, provides for operations to be funded to mid-2027, a year past the expected IPF Phase 2b clinical trial readout.” The company said a Phase IIb trial initiation should be expected in mid-2023.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content